Discover whether it's possible to have mixed dementia, specifically a combination of Alzheimer's and Lewy body dementia. This ...

A quick finger prick and a few drops of blood on a card that can be sent in regular mail—This approach could soon make ...

That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...

A once-a-day pill that targets the production of the stress hormone cortisol in the brain has the potential to be the “holy ...

Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...

Most discontinued anti-tau antibodies (red) targeted tau’s N-terminus. Of the antibodies currently in trials (green), bepranemab and E2814 presented results at CTAD, while JJ-63733657/posdinemab and ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

In the rapidly evolving field of neuroimaging, the convergence of engineering advancements and medical expertise is reshaping our approach to understanding and treating neurological disorders. This ...

Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer's; on track to generate top-line data H1 2025 - - Recent third-party clinical data esta ...

Alzheimer disease (AD) is the sixth leading cause of death in the United States and is projected to affect over 13 million ...

Healthy obesity is defined as having a BMI of 25 kg/m² or higher without metabolic diseases or with only one metabolic ...

We asked Dr. Joanne Pike, CEO of the Alzheimer's Association to help explain the challenges and hopes when it comes to this debilitating disease.